

ASCO 2020 Annual Meeting

May 29–31, 2020

Authors	Title	Presentation Type	Session	Link
Joyce F. Liu, Mark F. Brady, Ursula A. Matulonis, Austin Miller, Elise C. Kohn, Elizabeth M. Swisher, William P. Tew, Noelle Gillette Cloven , Carolyn Muller, David Bender, Richard G. Moore, David Paul Michelin, Steven E. Waggoner, Melissa Ann Geller, Keiichi Fujiwara, Stacy D. D'Andre, Michael Carney, Angeles Alvarez Secord, Katherine M. Moxley, Michael A. Bookman ; Dana-Farber Cancer Institute, Boston, MA; Roswell Park Cancer Institute, Buffalo, NY; Roswell Park Comprehensive Cancer Center, Buffalo, NY; Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD; University of Washington School of Medicine, Seattle, WA; Memorial Sloan Kettering Cancer Center, New York, NY; Texas Oncology, Ft. Worth, TX; University of New Mexico, Albuquerque, NM; University of Iowa, Iowa City, IA; University of Rochester Medical Center, Rochester, NY; Cancer Research Consortium of West Michigan, Grand Rapids, MI; Case Western Reserve University School of Medicine, University Hospitals of Cleveland, Cleveland, OH; University of Minnesota, Minneapolis, MN; Saitama Medical University International Medical Center, Hidaka, Japan; Sutter Medical Group, Sacramento, CA; University of Hawaii, Honolulu, HI; Duke Cancer Institute, Duke University Medical Center, Durham, NC; University of Oklahoma	A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer.	Oral	Gynecologic Cancer	https://meetinglibrary.asco.org/record/185456/abstract
Rodney Paul Rocconi, Erin E. Stevens, Justin N. Bottsford-Miller, Sharad A. Ghamande, Phylcia Aaron, Gladice Wallraven, Ernest Bogner, Meghan Manley, Staci Horvath, Luisa Manning, John J. Nemunaitis, Thomas J Herzog, Bradley J. Monk, Robert L. Coleman , Vigil Team; University of South Alabama, Mobile, AL; Billings Clinic, Billings, MT; Georgia Regents University, Augusta, GA; Gradalis, Inc., Carrollton, TX; Gradalis, Inc., Dallas, TX; Division of Gynecologic Oncology, The University of Cincinnati Cancer Institute, Cincinnati, OH; Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Phoenix, AZ; The University of Texas MD Anderson Cancer Center, Houston, TX	A phase I combination study of GMCSF/bi-shRNA(furin) DNA-transfected autologous tumor immunotherapy and atezolizumab in recurrent/refractory advanced-stage ovarian cancer: Efficacy assessment in BRCA1/2-wt patients.	Oral	Developmental Therapeutics—Immunotherapy	https://meetinglibrary.asco.org/record/185052/abstract
Amir Goldkorn, Catherine Tangen, Melissa Plets, Gareth Morrison, Alexander Cunha, Tong Xu, Jacek K. Pinski, Sue A. Ingles, Timothy Triche, Gary R. MacVicar, Daniel A. Vaena, Anthony W. Crispino, David James McConkey, Primo Lara, Maha H. A. Hussain, David I. Quinn, Nicholas J. Vogelzang , Ian Murchie Thompson, Neeraj Agarwal , SWOG GU Committee; Division of Medical Oncology, Department of Medicine, Keck School of Medicine and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA; SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA; University of Southern California, Los Angeles, CA; University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA; USC Keck School of Medicine Norris Comprehensive Cancer Center, Los Angeles, CA; USC/Children's Hospital Los Angeles, Los Angeles, CA; Illinois CancerCare PC, Peoria, IL; University of Iowa Hospitals and Clinics, Holden Comprehensive Cancer Center, Iowa City, IA; UsTOO Las Vegas, Las Vegas, NV; Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD; University of California, Sacramento, CA; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL; USC Norris Comprehensive Cancer Center, Los Angeles, CA; Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Christus Santa Rosa Hospital-Medical Center, San Antonio, TX; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT	Baseline circulating tumor cell (CTC) count as a prognostic marker of PSA response and progression in metastatic castrate sensitive prostate cancer (mCSPC): Results from SWOG S1216, a phase III randomized trial of androgen deprivation plus orteronel (cyp17 inhibitor) or bicalutamide.	Oral	Genitourinary Cancer—Prostate, Testicular, and Penile	https://meetinglibrary.asco.org/record/187404/abstract
Melissa Lynne Johnson, Anthony B. El-Khoueiry, Navid Hafez, Nehal J. Lakhani, Hirva Mamdani, Jordi Rodon Ahnert, Rachel E. Sanborn, Thang Ho, Rachel Li, Jana Waldes, Alexander I. Spira ; Sarah Cannon Research Institute, Nashville, TN; University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA; Yale University School of Medicine, New Haven, CT; START-Midwest, Grand Rapids, MI; Barbara Ann Karmanos Cancer Institute, Detroit, MI; MD Anderson University, Houston, TX; Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR; CytomX Therapeutics, Inc., South San Francisco, CA; Virginia Cancer Specialists, Fairfax, VA	CX-2029, a PROBODY drug conjugate targeting CD71 (transferrin receptor): Results from a first-in-human study (PROCLAIM-CX-2029) in patients (Pts) with advanced cancer.	Oral	Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology	https://meetinglibrary.asco.org/record/185085/abstract

Authors	Title	Presentation Type	Session	Link
Daniel Peter Petrylak, Xin Gao, Nicholas J. Vogelzang , Mary Harlow Garfield, Ian Taylor, Marcia Dougan Moore, Ronald Alan Peck, Howard A. Burris III; Smilow Cancer Center, Yale University, New Haven, CT; Dana-Farber Cancer Institute, Boston, MA; Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Arvinas Inc., New Haven, CT; Arvinas, Inc, New Haven, CT; Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN	First-in-human phase I study of ARV-110, an androgen receptor (AR) PROTAC degrader in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following enzalutamide (ENZ) and/or abiraterone (ABI).	Oral	Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology	https://meetinglibrary.asco.org/record/185083/abstract
Fiona Thistlethwaite, Aung Naing, Marta Gil-Martin, Patricia LoRusso, Manreet Randhawa, Ferry Eskens, Rachel E. Sanborn, Nataliya Volodymyrivna Uboha, Daniel C. Cho, Alexander I. Spira , Igor Bondarenko, Elizabeth Ruth Plummer, Javier Garcia-Corbacho, Iván Victoria, Javier Lavernia, Ignacio Melero, Elisabeth De Vries, William Garner, Hendrik-Tobias Arkenau, Johanna C. Bendell; The Christie NHS Foundation Trust and University of Manchester, Manchester, United Kingdom; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX; Institut Català d'Oncologia-IDIBELL, Hospital Duran I Reynals, Barcelona, Spain; Yale University School of Medicine, New Haven, CT; Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; Erasmus MC Cancer Institute, Rotterdam, Netherlands; Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR; UW Carbone Cancer Center, Madison, WI; NYU Clinical Cancer Center, New York, NY; Virginia Cancer Specialists, Fairfax, VA; City Clinical Hospital No4, Dnipro, Ukraine; Newcastle University, Newcastle upon Tyne, United Kingdom; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Universidad de Navarra, Center for Applied Medical Research (CIMA), Pamplona, Spain; University Medical Center Groningen, Groningen, Netherlands; CytomX Therapeutics, Inc., South San Francisco, CA; Sarah Cannon Research Institute UK Limited, London, United Kingdom; Sarah Cannon Research Institute/ Tennessee Oncology, Nashville, TN	PROCLAIM-CX-072: Analysis of patients with advanced solid tumors receiving long-term treatment with CX-072, a PD-L1 antibody therapeutic, as a single agent or in combination with ipilimumab.	Oral	Developmental Therapeutics—Immunotherapy	https://meetinglibrary.asco.org/record/186711/abstract
Sikander Ailawadhi, Hans Chulhee Lee, Jim Omel, Kathleen Toomey, James W. Hardin, Cristina Gasparetto, Sundar Jagannath, Robert M. Rifkin , Brian G. Durie, Mohit Narang , Howard R. Terebello, Lynne I. Wagner, Mazaher Dhalla, Mia He, Shankar Srinivasan, Prashant Ramesh Joshi, Suzanne Robinson, Rafat Abonour; Mayo Clinic, Jacksonville, FL; The University of Texas MD Anderson Cancer Center, Houston, TX; Myeloma Research Advocate/Advisor, Grand Island, NE; Steeplechase Cancer Center, Somerville, NJ; University of South Carolina, Columbia, SC; Duke University Medical Center, Durham, NC; Mount Sinai Hospital, New York, NY; Rocky Mountain Cancer Centers US Oncology, Denver, CO; Cedars-Sinai Medical Center, Los Angeles, CA; US Oncology Research, Columbia, MD; Providence Cancer Institute, Southfield, MI; Wake Forest School of Medicine, Winston-Salem, NC; Bristol-Myers Squibb, Summit, NJ; Celgene International Sàrl, A Bristol-Myers Squibb Company, Boudry, Switzerland; Indiana University, Indianapolis, IN	Impact of lenalidomide-bortezomib-dexamethasone (RVd) induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect MM Registry.	Poster	Hematologic Malignancies—Plasma Cell Dyscrasia	https://meetinglibrary.asco.org/record/187614/abstract
Christopher A. Yasechak , Rodolfo Eduardo Bordoni, Dipti Patel-Donnelly , Tim Larson , Jerome H. Goldschmidt , Ralph V. Boccia, Vivian Jean M. Cline , Andres Forero-Torres, Robert Brownell Sims, Trevor Newhook, Jonathan W. Friedberg; Willamette Valley Cancer Institute and Research Center/US Oncology Research, Eugene, OR; Georgia Cancer Specialists, Marietta, GA; Virginia Cancer Specialists, Fairfax, VA; Minnesota Oncology/The US Oncology Network, Minneapolis, MN; Oncology and Hematology Assoc of SW Virginia, Blacksburg, VA; Center for Cancer and Blood Disorders, Bethesda, MD; Texas Oncology-Round Rock Seton Williamson, Round Rock, TX; Seattle Genetics, Bothell, WA; Seattle Genetics Inc., Bothell, WA; University of Rochester Medical Center, Rochester, NY	Frontline brentuximab vedotin as monotherapy or in combination for older Hodgkin lymphoma patients.	Poster	Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia	https://meetinglibrary.asco.org/record/186830/abstract
Christopher A. Yasechak , Rodolfo Eduardo Bordoni, Victor Y. Yazbeck, Dipti Patel-Donnelly , Tim Larson , Robert Brownell Sims, Matthew Genyeh Mei; Willamette Valley Cancer Institute and Research Center/US Oncology Research, Eugene, OR; Georgia Cancer Specialists, Marietta, GA; Massey Cancer Center, Richmond, VA; FNVHO, Fairfax, VA; Minnesota Oncology/The US Oncology Network, Minneapolis, MN; Seattle Genetics, Bothell, WA; City of Hope Comprehensive Cancer Center, Duarte, CA	Frontline brentuximab vedotin in Hodgkin lymphoma and CD30-expressing peripheral T-cell lymphoma for older patients and those with comorbidities.	Poster	Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia	https://meetinglibrary.asco.org/record/191910/abstract

Authors	Title	Presentation Type	Session	Link
David Jacob Andorsky , Morton Coleman, Abdurraheem Yacoub, Jason M. Melear , Suzanne R. Fanning , Kathryn S. Kolibaba , Frederick Lansigan, Chris Reynolds, Grzegorz S. Nowakowski, Mecide Gharibo, Jung Ryun Ahn, Ju Li, Mathias J. Rummel, Jeff P. Sharman , on behalf of the MAGNIFY Trial Investigators; Rocky Mountain Cancer Centers/The US Oncology Network, Boulder, CO; Clinical Research Alliance Inc., Weill Cornell Medicine, New York, NY; University of Kansas Cancer Center, Westwood, KS; Texas Oncology-Austin, US Oncology Research, Austin, TX; Prisma Health, US Oncology Research, Greenville, SC; Compass Oncology, US Oncology Research, Vancouver, WA; Dartmouth-Hitchcock Medical Center, Lebanon, NH; IHA Hematology Oncology Consultants-Ann Arbor, Ypsilanti, MI; Mayo Clinic, Rochester, MN; Bristol-Myers Squibb, Summit, NJ; Justus-Liebig Universität, Giessen, Germany; Willamette Valley Cancer Institute and US Oncology Research Center, Eugene, OR	MAGNIFY phase IIIb interim analysis of induction R2 followed by maintenance in relapsed/refractory indolent NHL.	Poster	Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia	https://meetinglibrary.asco.org/record/186847/abstract
Arlene O. Siefker-Radtke, Andrea Necchi, Se Hoon Park, Jesús García-Donas, Robert A Huddart, Earle Frederick Burgess, Mark T. Fleming , Arash Rezazadeh, Begona Mellado, Sergei Varlamov, Monika Joshi, Ignacio Duran, Scott T. Tagawa, Yousef Zakharia, Min Fu, Ademi E. Santiago-Walker, Manish Monga, Anne OHagan, Silvia Mosher, Yohann Loriot, BLC2001 Study Group; The University of Texas MD Anderson Cancer Center, Houston, TX; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Samsung Medical Center, Department of Medicine, Seoul, South Korea; Fundacion Hospital de Madrid, Madrid, Spain; Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; Levine Cancer Institute, Charlotte, NC; Virginia Oncology Associates, US Oncology Research, Norfolk, VA; Norton Healthcare, Louisville, KY; Hospital Clínic of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain; Altai Regional Cancer Center, Barnaul, Russian Federation; Penn State Health Milton S. Hershey Medical Center, Hershey, PA; Department of Medical Oncology, Hospital Universitario Marqués de Valdecilla, Santander, Spain; Weill Cornell Medical College, New York, NY; University of Iowa and Holden Comprehensive Cancer Center, Iowa City, IA; Janssen Research and Development, Springhouse, PA	ERDAFITINIB in locally advanced or metastatic urothelial carcinoma (mUC): Long-term outcomes in BLC2001.	Poster	Genitourinary Cancer—Kidney and Bladder	https://meetinglibrary.asco.org/record/187469/abstract
Jeff P. Sharman , Danielle M. Brander, Anthony R. Mato, Nilanjan Ghosh, Stephen J. Schuster, Suman Kambhampati, John M. Burke , Frederick Lansigan, Marshall T. Schreeder, Scott D Lunin, Alexander Zweibach , Mikhail Shtivelband, Patrick M. Travis, Jason Claud Chandler, Kathryn S. Kolibaba , Peter Sportelli, Hari P. Miskin, Michael S. Weiss, Ian Flinn; Willamette Valley Cancer Institute and US Oncology Research Center, Eugene, OR; Duke University School of Medicine, Durham, NC; Center for CLL, Memorial Sloan Kettering Cancer Center, New York, NY; Levine Cancer Institute, Atrium Health, Charlotte, NC; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA; University of Kansas Medical Center, Sarah Cannon Research Institute, Kansas City, KS; Rocky Mountain Cancer Centers/US Oncology Research, Aurora, CO; Dartmouth-Hitchcock Medical Center, Lebanon, NH; Clearview Cancer Institute, Huntsville, AL; Florida Cancer Specialists, Sarah Cannon Research Institute, Sarasota, FL; Cancer Care Centers of South Texas/US Oncology Research, New Braunfels, TX; Ironwood Cancer and Research Centers, Chandler, AZ; Highlands Oncology Group, Fayetteville, AR; West Cancer Center, Memphis, TN; Compass Oncology, US Oncology Research, Vancouver, WA; TG Therapeutics, Inc., New York, NY; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN	Effect of adding ublituximab to ibrutinib on PFS, ORR, and MRD negativity in previously treated high-risk chronic lymphocytic leukemia: Final results of the GENUINE phase III study.	Poster	Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia	https://meetinglibrary.asco.org/record/187446/abstract
Federico Cappuzzo, Martin Reck, Mark A. Socinski, Tony S. K. Mok, Robert M. Jotte , Gene Grant Finley, Delvys Rodriguez-Abreu, Joachim Aerts, Howard West, Makoto Nishio, Liza C Villaruz, Shelly Coleman, Anthony Lee, Hans Kristian Volla, Wei Yu, Roxana Ioana Sufan, Ilze Bara, Fabrice Barlesi; Azienda Unità Sanitaria Locale della Romagna, Ravenna, Italy; LungenClinic, Airway Research Center North (ARCN), German Center for Lung Research (DZL), Grosshansdorf, Germany; AdventHealth Cancer Institute, Orlando, FL; The Chinese University of Hong Kong, Hong Kong, China; US Oncology Research and Rocky Mountain Cancer Centers, Denver, CO; Department of Medical Oncology, Allegheny General Hospital, Pittsburgh, PA; Hospital Universitario Insular de Gran Canaria, Las Palmas De Gran Canaria, Spain; Department of Pulmonology, Erasmus University Medical Center, Rotterdam, Netherlands; City of Hope Comprehensive Cancer Center, Duarte, CA; Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan; University of Pittsburgh Medical Center-Hillman Cancer Center, Pittsburgh, PA; Genentech, Inc., South San Francisco, CA; F. Hoffmann-La Roche, Ltd., Basel, Switzerland; Aix-Marseille University, Assistance Publique Hôpitaux de Marseille, Marseille, France	IMpower150: Exploratory analysis of brain metastases development.	Poster	Lung Cancer—Non-Small Cell Metastatic	https://meetinglibrary.asco.org/record/184862/abstract

Authors	Title	Presentation Type	Session	Link
D. Ross Camidge, Huifeng Niu, Hye Ryun Kim, James Chih-Hsin Yang, Myung-Ju Ahn, Jacky Yu-Chung Li, Maximilian Hochmair, Angelo Delmonte, Alexander I. Spira , Rosario Garcia Campelo, Fabrice Barlesi, Geoffrey Liu, Marcello Tiseo, Cong Li, Miguel Williams, Hyunjin Shin, Pingkuan Zhang, Sanjay Popat; Division of Medical Oncology, University of Colorado, Anschutz Medical Campus, Aurora, CO; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea; National Taiwan University Hospital, Taipei, Taiwan; Samsung Medical Center, Seoul, South Korea; Queen Elizabeth Hospital, Hong Kong United Oncology Centre, Kowloon, China; Department of Respiratory and Critical Care Medicine, Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Vienna, Austria; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCS, Meldola, Italy; Virginia Cancer Specialists and US Oncology Research, The Woodlands, TX; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Aix-Marseille University, Marseille, France; Princess Margaret Cancer Centre, Toronto, ON, Canada; University Hospital of Parma, Parma, Italy; The Royal Marsden Hospital and The Institute of Cancer Research, London, United Kingdom	Correlation of baseline molecular and clinical variables with ALK inhibitor efficacy in ALTA-1L.	Poster	Lung Cancer–Non-Small Cell Metastatic	https://meetinglibrary.asco.org/record/186085/abstract
Heather Christine Beckwith, Diana Cristina Medgyesy, Jame Abraham, Rita Nanda, Katherine H. R. Tkaczuk, Ian E. Krop, Lajos Pusztai, Shanu Modi, Monica M. Mita, Jennifer M. Specht, Sara A. Hurvitz, Hyo S. Han, Kevin Kalinsky, Sharon Wilks , Joyce O'Shaughnessy , Lowell L. Hart, Hope S. Rugo, Zahi Ibrahim Mitri, Phillip M. Garfin, Howard A. Burris III; Univ of Minnesota, Minneapolis, MN; Front Range Cancer Spclsts, Fort Collins, CO; NSABP Foundation and Cleveland Clinic, Cleveland, OH; The University of Chicago, Chicago, IL; University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD; Dana-Farber Cancer Institute, Boston, MA; Yale University, New Haven, CT; Memorial Sloan Kettering Cancer Center, New York, NY; Cedars-Sinai Comprehensive Cancer Center, Los Angeles, CA; University of Washington, Seattle, WA; David Geffen School of Medicine at UCLA, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; Herbert Irving Comprehensive Cancer Center, New York, NY; Texas Oncology-San Antonio Northeast, US Oncology, San Antonio, TX; Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; Florida Cancer Specialists and Research Institute, Fort Myers, FL; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Oregon Health and Science University, Portland, OR; Seattle Genetics, Bothell, WA; Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN	SGNLVA-001: A phase I open-label dose escalation and expansion study of SGN-LIV1A administered weekly in breast cancer.	Poster	Breast Cancer–Metastatic	https://meetinglibrary.asco.org/record/191857/abstract
Mansoor Raza Mirza, Antonio Gonzalez Martin, Whitney Graybill, David M. O'Malley, Lydia Gaba, Oi Wah S. Yap, Eva M. Guerra, Peter Graham Rose, Jean-Francois Baurain, Sharad A. Ghamande, Hannelore denys, Emily Prendergast , Carmela Pisano, Philippe Follana, Klaus Baumann, Paula Calvert, Jacob Korach, Yong Li, Divya Gupta, Bradley J. Monk ; Nordic Society of Gynecologic Oncology (NSGO) and Rigshospitalet–Copenhagen University Hospital, Copenhagen, Denmark; Clínica Universidad de Navarra, Madrid, Spain; Medical University of South Carolina, Charleston, SC; The Ohio State University-James Comprehensive Cancer Center, Columbus, OH; Hospital Clinic de Barcelona, Medical Oncology Department, Barcelona, Spain; University Gynecologic Oncology, Atlanta, GA; Hospital Universitario Ramón y Cajal, Madrid, Spain; Cleveland Clinic, Cleveland, OH; Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium; Georgia Cancer Center, Augusta University, Augusta, GA; BGOG and Ghent University Hospital, Ghent, Belgium; Minnesota Oncology, Minneapolis, MN; Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy; Centre Antoine Lacassagne, Nice, France; Klinikum der Stadt Ludwigshafen, Department of Gynecology and Obstetrics, Ludwigshafen Am Rhein, Germany; Cancer Trials Ireland, Dublin, Ireland; Sackler Medical School Tel Aviv University, The Chaim Sheba Medical Center, Department of Oncology, Ramat Gan, Israel; GlaxoSmithKline, Waltham, MA; Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Phoenix, AZ	Evaluation of an individualized starting-dose of niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study.	Poster	Gynecologic Cancer	https://meetinglibrary.asco.org/record/187463/abstract

Authors	Title	Presentation Type	Session	Link
Bradley J. Monk , Ignacio Romero, Whitney Graybill, Cristina Churrucua, David M. O'Malley, Bente Lund, Oi Wah S. Yap, Jean-Francois Baurain, Peter Graham Rose, Hannelore denys, Sharad A. Ghamande, Carmela Pisano, Michel Fabbro, Elena Ioana Braicu, Paula Calvert, Amnon Amit, Emily Prendergast , Ashley Milton, Zhi-Yi Zhang, Antonio Gonzalez Martin; Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Phoenix, AZ; Medical Oncology, Fundación Instituto Valenciano de Oncología, Valencia, Spain; Medical University of South Carolina, Charleston, SC; Medical Oncology, Hospital Universitario Donostia, Gipuzkoa, Spain; The Ohio State University-James Comprehensive Cancer Center, Columbus, OH; Aalborg University Hospital, Aalborg, Denmark; University Gynecologic Oncology, Atlanta, GA; Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium; Cleveland Clinic, Cleveland, OH; BGOG and Ghent University Hospital, Ghent, Belgium; Georgia Cancer Center, Augusta University, Augusta, GA; Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy; Institut du Cancer de Montpellier, Montpellier, France; Department of Gynecology, Charité Medical University, Berlin, Germany; Cancer Trials Ireland, Dublin, Ireland; ISGO and GYN-ONCOLOGY-Rambam Health Care Campus, Haifa, Israel; Minnesota Oncology, Minneapolis, MN; GlaxoSmithKline, Waltham, MA; Clínica Universidad de Navarra, Madrid, Spain	Niraparib exposure-response relationship in patients (pts) with newly diagnosed advanced ovarian cancer (AOC).	Poster	Gynecologic Cancer	https://meetinglibrary.asco.org/record/186897/abstract
Joyce O'Shaughnessy , Rebecca L. Moroosse, Sunil Babu, Kakhaber Baramidze, David Chan, Stuart P. Leitner, Gia Nemsadze, Peter Ordentlich, Christine Quaranto, Michael L. Meyers, Valeria González Graf, Taunya J. Smith, Valerie Bee-Munteanu, Rodrigo Fresco, Dennis J. Slamon; Baylor Charles A. Sammons Cancer Center, US Oncology and Texas Oncology, Dallas, TX; University of Florida Health Cancer Center-Orlando Health, Orlando, FL; Fort Wayne Medical Oncology and Hematology, Fort Wayne, IN; Golden Fleece 21 Century Health House Ltd, Tbilisi, Georgia; Cancer Care Assoc-TMPN, Redondo Beach, CA; Cancer Ctr St Barnabas, Livingston, NJ; Institute of Clinical Oncology, Tbilisi, Georgia; Syndax Pharmaceuticals, Lexington, MA; Syndax Pharmaceutical Inc., Waltham, MA; Syndax Pharmaceuticals, Inc., New York, NY; Translational Research in Oncology, Montevideo, Uruguay; Translational Research in Oncology, Los Angeles, CA; Translational Research in Oncology, Paris, France; UCLA Medical Center, Santa Monica, CA	Results of ENCORE 602 (TRIO025), a phase II, randomized, placebo-controlled, double-blinded, multicenter study of atezolizumab with or without entinostat in patients with advanced triple-negative breast cancer (aTNBC).	Poster	Poster Discussion Session	https://meetinglibrary.asco.org/record/185152/abstract
Nina D'Abreo, Jennifer A. Crozier, Adam Brufsky, Ian Grady, Sami Diab , Blanche H. Mavromatis, Carrie L. Dul, Rakhshanda Layeequr Rahman, Laura A. Lee, Vijayakrishna K. Gadi, Sarah Untch, Erin Yoder, Heather M. Kling, Amy Truitt, William Audeh, FLEX Investigators Group; NYU Winthrop Hospital, Mineola, NY; Baptist MD Anderson Cancer Center, Jacksonville, FL; University of Pittsburgh Medical Center, Division of Hematology Oncology, Pittsburgh, PA; North Valley Breast Clinic, Redding, CA; Colorado Integrative Cancer Center, Greenwood Village, CO; Western Maryland Health Syst, Cumberland, MD; Ascension St John Hospital, Detroit, MI; Texas Tech University Health Sciences Center, Breast Center of Excellence, Amarillo, TX; Comprehensive Cancer Center, Palm Springs, CA; Fred Hutchinson Cancer Research Center, Seattle, WA; Agendia, Irvine, CA; Medical Affairs, Agendia, Inc., Irvine, CA; Agendia, Inc., Irvine, CA	The FLEX real-world data platform explores new gene expression profiles and investigator-initiated protocols in early stage breast cancer.	Poster	Health Services Research and Quality Improvement	https://meetinglibrary.asco.org/record/191745/abstract
Edward B. Garon, Andrea Ardizzoni, Fabrice Barlesi, Byoung Chul Cho, Pedro De Marchi, Yasushi Goto, Dariusz M. Kowalski, Shun Lu, Luis G. Paz-Ares, David R. Spigel, Alexander I. Spira , Michael Thomas, Mimi Leung, Jason Baum, Zewen Zhu, Maria do Socorro Oliveira Portella, James Chih-Hsin Yang; David Geffen School of Medicine, University of California/TRIO-US Network, Los Angeles, CA; University of Bologna, Bologna, Italy; Aix Marseille University, CNRS, INSERM, Marseille, France; Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea; Hospital de Câncer de Barretos, São Paulo, Brazil; Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan; Department of Lung Cancer and Thoracic Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland; Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China; Hospital Universitario 12 de Octubre, Madrid, Spain; Sarah Cannon Research Institute, Nashville, TN; Virginia Cancer Specialists, Fairfax, VA; Thoraxklinik at Heidelberg University Hospital, Heidelberg, Germany; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Novartis Institutes for BioMedical Research, Cambridge, MA; National Taiwan University Hospital, Taipei, Taiwan	CANOPY-A: A phase III, multicenter, randomized, double-blind, placebo-controlled trial evaluating canakinumab as adjuvant therapy in patients (pts) with completely resected non-small cell lung cancer (NSCLC).	Poster	Lung Cancer-Non-Small Cell Local-Regional/ Small Cell/Other Thoracic Cancers	https://meetinglibrary.asco.org/record/191875/abstract

Authors	Title	Presentation Type	Session	Link
Rebecca Christian Arend, Bradley J. Monk , Robert Allen Burger, Thomas J. Herzog, Jonathan A. Ledermann, Kathleen N. Moore, Angeles Alvarez Secord, Roni Shapira, Krishnansu Sujata Tewari, Marilyn Huang, Amnon Amit, Tamar Rachmilewitz Minei, Dror Harats, Richard T. Penson; University of Alabama at Birmingham, Birmingham, AL; Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Phoenix, AZ; Department of Obstetrics & Gynecology, Division of Gynecologic Oncology, University of Pennsylvania, Philadelphia, PA; University of Cincinnati, University of Cincinnati Cancer Institute, Cincinnati, OH; University College London Cancer Institute, London, United Kingdom; University of Oklahoma Medical Center, Oklahoma City, OK; Duke Cancer Institute, Duke University Medical Center, Durham, NC; Chaim Sheba Medical Center, Tel Hashomer, Israel; The Division of Gynecologic Oncology at the University of California, Irvine, Orange, CA; Magee-Womens Hospital of UPMC, Pittsburgh, PA; ISGO and GYN-ONCOLOGY-Rambam Health Care Campus, Haifa, Israel; VBL Therapeutics, Israel, Israel; VBL Therapeutics, Modiin, Israel; Harvard Medical School, Massachusetts General Hospital, Boston, MA	Clinical trial in progress: Pivotal study of VB-111 combined with paclitaxel versus paclitaxel for treatment of platinum-resistant ovarian cancer (OVAL, VB-111-701/ GOG-3018).	Poster	Gynecologic Cancer	https://meetinglibrary.asco.org/record/191693/abstract
David R. Spigel, Merrill Kingman Shum, Jeffrey Gary Schneider, Robert M. Jotte , Jennifer L. Eisenstein, Viralkumar K. Bhandari, Kartik Konduri , Annie Hung, Rebecca R. Hozak, David Raymond Ferry, Leena Gandhi, Bo H. Chao, Igor I. Rybkin; Sarah Cannon Research Institute, Nashville, TN; The Onc Inst of Hope and Innovation, Whittier, CA; NYU Winthrop Hospital, Mineola, NY; US Oncology Research and Rocky Mountain Cancer Centers, Denver, CO; CPMG/Kaiser, Lafayette, CO; Florida Cancer Spclst, Tallahassee, FL; Texas Oncology/The US Oncology Network, Dallas, TX; Eli Lilly and Company, Indianapolis, IN; Eli Lilly and Company, New York, NY; Henry Ford Health System, Wayne State University School of Medicine, Detroit, MI	Randomized phase II study of pembrolizumab (P) alone versus pegilodocakin (PEG) in combination with P as first-line (1L) therapy in patients (pts) with stage IV non-small cell lung cancer (NSCLC) with high PD-L1 expression (CYPRESS 1).	Poster	Lung Cancer—Non-Small Cell Metastatic	https://meetinglibrary.asco.org/record/184865/abstract
Zeynep Eroglu, Charles Lance Cowey , John Soong, Daniel McCormick, Phoebe Fan, Jimmy Chen, Mohamed Elgendy, Sekwon Jang, Anne Lynn S. Chang; Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Baylor-Sammons Cancer Ctr TOPA, Frisco, TX; Senhwa Biosciences, San Diego, CA; Senhwa Biosciences, New Taipei City, Taiwan; Inova Schar Cancer Institute, Fairfax, VA; Department of Dermatology, Stanford University School of Medicine, Redwood City, CA	A phase I study of CX-4945 administered orally twice daily to patients with advanced basal cell carcinoma.	Poster	Melanoma/Skin Cancers	https://meetinglibrary.asco.org/record/191797/abstract
Martin Gutierrez, Georgina V. Long, Claire Frances Friedman, Donald A. Richards , Bradley Corr, Bruno R. Bastos , Marc Isamu Uemura, Paul R. Conkling , Victor Moreno, William Jeffery Edenfield , Carlos Roberto Becerra , Sarina Anne Piha-Paul, Amy C. Peterson, Michelle Brown, Lee P. James, Ming Zheng, Jieying Jiang, Georgia Kollia, Ailsa Swijter, Paolo Antonio Ascierto; Hackensack University Medical Center, Hackensack, NJ; Melanoma Institute Australia, The University of Sydney, Royal North Shore Hospital, Mater Hospital, Sydney, Australia; Memorial Sloan Kettering Cancer Center, New York, NY; US Oncology Research, Tyler, TX; University of Colorado, Aurora, CO; Cleveland Clinic, Weston, FL; The University of Texas MD Anderson Cancer Center, Houston, TX; Virginia Oncology Associates, Norfolk, VA; START Madrid-FJD, Fundación Jiménez Díaz University Hospital, Madrid, Spain; Institute for Translational Oncology Research, Prisma Health-Upstate Cancer Institute, Greenville, SC; Baylor University Medical Center, Dallas, TX; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX; CytomX Therapeutics, San Francisco, CA; Bristol-Myers Squibb, Plainsboro, NJ; Bristol-Myers Squibb, Princeton, NJ; Fondazione IRCCS-Istituto Nazionale dei Tumori, Naples, Italy	Anti-CTLA-4 probody BMS-986249 alone or in combination with nivolumab in patients with advanced cancers: Initial phase I results.	Poster	Developmental Therapeutics—Immunotherapy	https://meetinglibrary.asco.org/record/188946/abstract
Ben George, Donald A. Richards , William Jeffery Edenfield , Steven L. Warner, Lars Mouritsen, Reyna Bishop, Stephen Patrick Anthony, David Bearss, Nicholas J. Vogelzang , Clifford Whatcott; Froedtert & The Medical College of Wisconsin, Milwaukee, WI; US Oncology Research, Tyler, TX; Institute for Translational Oncology Research, Prisma Health-Upstate Cancer Institute, Greenville, SC; Tolero Pharmaceuticals, Inc., Lehi, UT; Tolero Pharmaceuticals, Inc, Lehi, UT; Comprehensive Cancer Centers of Nevada, Las Vegas, NV	A phase I, first-in-human, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-1287 administered daily to patients with advanced solid tumors.	Poster	Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology	https://meetinglibrary.asco.org/record/188088/abstract

Authors	Title	Presentation Type	Session	Link
Ian Flinn, Mazyar Shadman, Benjamin Bruce Freeman, Dih-Yih Chen, Xiaoping Zhang, Aileen Cohen, Sunhee K. Ro, Jane Huang, Jeff P. Sharman ; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA; Summit Medical Group, Florham Park, NJ; BeiGene USA, Inc., San Mateo, CA; Willamette Valley Cancer Institute and Research Center, Eugene, OR	Trial in progress: a phase II, multicenter, single-arm study of zanubrutinib (BGB-3111) in patients with previously treated chronic lymphocytic leukemia/ small lymphocytic lymphoma intolerant of prior treatment with ibrutinib.	Poster	Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia	https://meetinglibrary.asco.org/record/191895/abstract
Daniel Peter Petrylak, Scott T. Tagawa, Rohit K. Jain, Manojkumar Bupathi , Arjun Vasant Balar, Arash Rezazadeh, Saby George, Phillip Lee Palmbos, Luke T. Nordquist, Nancy B. Davis, Nicholas J. Vogelzang , Chethan Ramamurthy, Cora N. Sternberg, Yohann Lorient, Neeraj Agarwal, Quan Hong, Allison Gladden, Charu Kanwal, Trishna Goswami, Petros Grivas; Yale University School of Medicine, New Haven, CT; Weill Cornell Medical College, New York, NY; Lee Moffitt Cancer Center, Tampa, FL; Rocky Mountain Cancer Centers, Littleton, CO; New York University Langone Health, New York, NY; Norton Cancer Institute, Louisville, KY; Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY; University of Michigan Rogel Cancer Center, Ann Arbor, MI; Urology Cancer Center and GU Research Network, Omaha, NE; Vanderbilt Ingram Cancer Center, Nashville, TN; Comprehensive Cancer Centers of Nevada, Las Vegas, NV; University of Texas Health Science Center at San Antonio, San Antonio, TX; Weill Cornell Medicine, New York, NY; Institut de Cancérologie Gustave Roussy, Villejuif, France; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Immunomedics, Inc., Morris Plains, NJ; University of Washington, Seattle, WA	Early results of TROPHY-U-01 Cohort 2: Sacituzumab govitecan (SG) in platinum-ineligible patients (pts) with metastatic urothelial cancer (mUC) who progressed after prior checkpoint inhibitor (CPI) therapy.	Poster	Genitourinary Cancer—Kidney and Bladder	https://meetinglibrary.asco.org/record/187301/abstract
Ivor John Percent, Craig H. Reynolds , Kartik Konduri , Matthew Thomas Whitehurst, Emmanuel A. Nidhiri, Ronald H. Yanagihara, Misako Nagasaka, Marshall T Schreeder, James Uyeki , Georges Azzi, Krishna Kishore Pachipala, Jason C. Comer, Rachel E. Lerner, Ticiana Leal, Delia Alvarez, Saskia T.C. Neuteboom, Natasha Reddinger, xiaohong yan, Ronald L. Shazer, David Michael Waterhouse ; Florida Cancer Specialists South/Sarah Cannon Research Institute, Port Charlotte, FL; Florida Cancer Affiliates, Ocala, FL; Texas Oncology/The US Oncology Network, Dallas, TX; Hematology Oncology Associates of Fredericksburg, Fredericksburg, VA; Commonwealth Cancer Ctr, Danville, KY; Straub Clinic, Honolulu, HI; Barbara Ann Karmanos Cancer Institute, Detroit, MI; Clearview Cancer Institute, Huntsville, AL; Texas Onc PA, Austin, TX; Holy Cross Medical Group, Michael and Dianne Bienes Comprehensive Cancer Center, Fort Lauderdale, FL; Millenium Physicians-North Houston, Houston, TX; Overlake Medical Clinics, Bellevue, WA; Frauenshuh Cancer Center and Park Nicollet Institute, Minneapolis, MN; University of Wisconsin Carbone Cancer Center, Madison, WI; Mirati Therapeutics, Inc., San Diego, CA; Mirati, San Diego, CA; OHC (Oncology Hematology Care), Inc., Cincinnati, OH	Phase III trial of sitravatinib plus nivolumab vs. docetaxel for treatment of NSCLC after platinum-based chemotherapy and immunotherapy (SAPPHIRE).	Poster	Lung Cancer—Non-Small Cell Metastatic	https://meetinglibrary.asco.org/record/191817/abstract
Debra L. Richardson, Minal A. Barve, James Fredric Strauss, Susanna Varkey Ulahannan, Kathleen N. Moore, Erika Paige Hamilton, Melissa Lynne Johnson, Kyriakos P. Papadopoulos, Corrine Zarwan, Charles K Anderson , Joseph Buscema , Deborah Blythe Doroshov, William Jeffery Edenfield , Ursula A. Matulonis, Timothy F. Burns, Dirk Huebner, Valerie Malyvanh Jansen, Rebecca Mosher, Donna Jarlenski, Anthony W. Tolcher; Stephenson Cancer Center/Sarah Cannon Research Institute at the University of Oklahoma Health Sciences Center, Oklahoma City, OK; Mary Crowley Cancer Research Center, Dallas, TX; Sarah Cannon Research Institute and the University of Oklahoma Health Sciences Center, Nashville, TN and Oklahoma City, OK; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Sarah Cannon Research Institute, Tennessee Oncology, PLLC, Nashville, TN; South Texas Accelerated Research Therapeutics, LLC, San Antonio, TX; Lahey Hospital and Medical Center, Burlington, MA; Willamette Valley Cancer Institute, Eugene, OR; Arizona Oncology Associates, Tucson, AZ; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY; Institute for Translational Oncology Research, Prisma Health-Upstate Cancer Institute, Greenville, SC; Dana-Farber Cancer Institute, Boston, MA; University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, Pittsburgh, PA; Mersana Therapeutics, Inc., Cambridge, MA; NEXT Oncology, San Antonio, TX	Phase I expansion study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC): Preliminary efficacy, safety, and biomarker results in patients with previously treated metastatic ovarian cancer (OC) or non-small cell lung cancer (NSCLC).	Poster	Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology	https://meetinglibrary.asco.org/record/188449/abstract

Authors	Title	Presentation Type	Session	Link
Siamak Daneshmand, Petros Grivas, Srikala S. Sridhar, Shilpa Gupta, Joaquim Bellmunt, Guru Sonpavde, Mark T. Fleming , Seth P. Lerner, Yohann Lorient, Hao Wang, Hiywot Takkele, Corina Andresen, Jessica Rearden, Craig Berman, Sumanta K. Pal; Keck School of Medicine of USC, Los Angeles, CA; University of Washington, Seattle, WA; Princess Margaret Cancer Centre, Toronto, ON, Canada; Cleveland Clinic Foundation, Cleveland, OH; Beth Israel Deaconess Medical Center, Boston, MA; Department of Genitourinary Oncology, Dana Farber Cancer Institute, Boston, MA; Virginia Oncology Associates, Hampton, VA; Baylor College of Medicine, Houston, TX; Institut Gustave Roussy, Paris, France; QED Therapeutics Inc., San Francisco, CA; City of Hope Comprehensive Cancer Center, Duarte, CA	PROOF 302: A randomized, double-blind, placebo-controlled, phase III trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma harboring susceptible FGFR3 alterations.	Poster	Genitourinary Cancer—Kidney and Bladder	https://meetinglibrary.asco.org/record/191678/abstract
Michael J. Morris, Ronald De Wit, Nicholas J. Vogelzang , Scott T. Tagawa, Celestia S. Higano; Memorial Sloan Kettering Cancer Center, New York, NY; Erasmus MC, Rotterdam, Netherlands; Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Weill Cornell Medical College, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA	A phase III trial of docetaxel versus docetaxel and radium-223 (Ra-223) in patients with metastatic castration-resistant prostate cancer (mCRPC): DORA.	Poster	Genitourinary Cancer—Prostate, Testicular, and Penile	https://meetinglibrary.asco.org/record/191709/abstract
Richard R. Furman, John C. Byrd, Roger G. Owen, Susan Mary O'Brien, Jennifer R. Brown, Peter Hillmen, Deborah Marie Stephens, Priti Patel, Liat Schwartz-Sagi, Marshall Baek, Beth Christian, Martin J.S. Dyer, Matthew J. Streetly, Clare Chui Ling Sun, Simon Rule, Michael Wang, Paolo Ghia, Wojciech Jurczak, John M. Pagel, Jeff P. Sharman ; Weill Cornell Medicine, New York Presbyterian Hospital, New York, NY; The Ohio State University Comprehensive Cancer Center, Columbus, OH; St. James's University Hospital, Leeds, United Kingdom; Chao Family Comprehensive Cancer Center, University of California, Irvine, CA; Dana-Farber Cancer Institute, Boston, MA; University of Utah Huntsman Cancer Institute, Salt Lake City, UT; Acerta Pharma, South San Francisco, CA; The Ernest and Helen Scott Haematological Research Institute, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom; Guy's Hospital, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom; National Heart, Lung, and Blood Institute, Bethesda, MD; Plymouth University Medical School, Plymouth, United Kingdom; The University of Texas MD Anderson Cancer Center, Houston, TX; Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy; Maria Skłodowska-Curie National Institute of Oncology, Krakow, Poland; Swedish Cancer Institute, Seattle, WA; Willamette Valley Cancer Institute/US Oncology, Eugene, OR	Safety of acalabrutinib (Acala) monotherapy in hematologic malignancies: Pooled analysis from clinical trials.	Poster	Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia	https://meetinglibrary.asco.org/record/186826/abstract
Sara M. Tolaney, Kevin Kalinsky, Virginia G. Kaklamani, David R. D'Adamo, Gürsel Aktan, Michaela L. Tsai, Ruth O'Regan, Peter A. Kaufman, Sharon Wilks , Eleni Andreopoulou, Debra A. Patt , Yuan Yuan, Grace Wang , Dongyuan Xing, Ella Kleynerman, Vassiliki Karantz, Sami Diab ; Dana-Farber Cancer Institute, Boston, MA; Columbia University Irving Medical Center, New York, NY; University of Texas Health Science Center, San Antonio, TX; Eisai Inc., Woodcliff Lake, NJ; Merck & Co., Inc., Kenilworth, NJ; Minnesota Oncology Hematology, Minneapolis, MN; University of Wisconsin Carbone Cancer Center, Madison, WI; University of Vermont Medical Center, the UVM Cancer Center, and the Larner College of Medicine at the University of Vermont, Burlington, VT; Texas Oncology-San Antonio Northeast, US Oncology, San Antonio, TX; Weill Cornell Medicine, New York, NY; Texas Oncology, Austin, TX; City of Hope National Medical Center, Duarte, CA; Miami Cancer Institute-Baptist Health South Florida, Miami, FL; Rocky Mountain Cancer Center-Aurora, Aurora, CO	A phase Ib/II study of eribulin (ERI) plus pembrolizumab (PEMBRO) in metastatic triple-negative breast cancer (mTNBC) (ENHANCE 1).	Poster	Poster Discussion Session	https://meetinglibrary.asco.org/record/185133/abstract
Keunchil Park, Thomas John, Sang-We Kim, Jong Seok Lee, Catherine A. Shu, Dong-Wan Kim, Santiago Viteri Ramirez, Alexander I. Spira , Joshua K. Sabari, Ji-Youn Han, Jose Manuel Trigo, Chee Khooon Lee, Ki Hyeong Lee, Nicolas Girard, Patricia A Lorenzini, John Xie, Amy Roshak, Meena Thayu, Roland Elmar Knoblauch, Byoung Chul Cho, on behalf of the CHRYSALIS Investigators; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; Department of Medical Oncology, Austin Health, Heidelberg, Australia; Asan Medical Center, Seoul, Korea, Republic of (South); Seoul National University Bundang Hospital, Seongnam, South Korea; Columbia University Medical Center, New York, NY; Seoul National University Hospital, Seoul, South Korea; Hospital Universitari Dexeus, Barcelona, Spain; Virginia Cancer Specialists, Fairfax, VA; New York University School of Medicine, New York, NY; National Cancer Center, Gyeonggi-Do, South Korea; Hospital Universitario Virgen de la Victoria, Málaga, Spain; St George Hospital, Kogarah, Australia; Chungbuk National University Hospital, Cheongju, South Korea; Institut Curie, Paris, France; Janssen Research & Development, LLC, Spring House, PA; Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea	Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC).	Poster	Lung Cancer—Non-Small Cell Metastatic	https://meetinglibrary.asco.org/record/184802/abstract

Authors	Title	Presentation Type	Session	Link
Amber Kleckner, Nikesha Gilmore, Elizabeth Belcher, Allison Magnuson, Richard Francis Dunne, Ian Kleckner, Huiwen Xu, Eva Culakova, Megan Wells, Nicholas J. Vogelzang , Elie G. Dib, Valerie Targia, Luke Joseph Peppone, Karen Michelle Mustian, Supriya Gupta Mohile; University of Rochester Medical Center, Rochester, NY; University of Rochester James Wilmot Cancer Institute, Rochester, NY; Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Michigan Cancer Research Consortium (NCORP), Ann Arbor, MI; Stakeholders for the Care and Research of Oncology Elders (SCOREBoard) Advisory Committee, Rochester, NY	Communication about comorbidities among 527 older patients with advanced cancer and their oncologists and caregivers: A multisite cluster-randomized controlled trial.	Poster	Symptoms and Survivorship	https://meetinglibrary.asco.org/record/187998/abstract
Aaron Elliott Lisberg, Jacob Sands, Toshio Shimizu, Jonathan Greenberg, Penny Phillips, Ferdinand M. Guevara, Yutaka Noguchi, Tadashi Toki, Alexander I. Spira , Noboru Yamamoto, Melissa L. Johnson, Funda Meric-Bernstam, Kiyotaka Yoh, Edward B. Garon, Rebecca Suk Heist; Department of Medicine, Division of Hematology/Oncology, UCLA, Los Angeles, CA; Lahey Hospital and Medical Center, Boston, MA; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan; Daiichi Sankyo, Basking Ridge, NJ; Daiichi Sankyo Inc, Basking ridge, NJ; Daiichi Sankyo Inc., Basking Ridge, NJ; Daiichi Sankyo, Co., Ltd., Tokyo, Japan; Daiichi Sankyo Co., Ltd., Tokyo, Japan; Virginia Cancer Specialists, Fairfax, VA; Sarah Cannon Research Institute, Nashville, TN; University of Texas MD Anderson Cancer Center, Houston, TX; National Cancer Center Hospital East, Kashiwa, Japan; David Geffen School of Medicine, University of California/TRIO-US Network, Los Angeles, CA; Massachusetts General Hospital, Boston, MA	Dose escalation and expansion from the phase I study of DS-1062, a trophoblast cell-surface antigen 2 (TROP2) antibody drug conjugate (ADC), in patients (pts) with advanced non-small cell lung cancer (NSCLC).	Poster	Lung Cancer—Non-Small Cell Metastatic	https://meetinglibrary.asco.org/record/184866/abstract
Christopher J. Hoimes, Nabil Adra, Mark T. Fleming , Hristos Z. Kaimakliotis, Joel Picus, Zachary L Smith, Radhika Walling, Edouard John Trabulsi, Jean H. Hoffman-Censits, Michael O. Koch, Clint Cary, Robert Abouassaly, Cheryl Eitman, Pingfu Fu, Gordon Goolamier, Adam C Calaway, Lee Evan Ponsky, William Kevin Kelly; Duke Cancer Institute, Durham, NC; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Virginia Oncology Associates, US Oncology Research, Norfolk, VA; Indiana University Simon Cancer Center, Indianapolis, IN; Washington University in St. Louis School of Medicine, St. Louis, MO; Washington University School of Medicine, St Louis, MO; Community Cancer Center, Indianapolis, IN; Department of Urology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Indiana University School of Medicine, Indianapolis, IN; Glickman Urology and Kidney Institute, Cleveland Clinic Foundation, Cleveland, OH; University Hospitals Seidman Cancer Center, Cleveland, OH; Department of Population and Quantitative Health Science, Case Western Reserve University, Cleveland, OH; Case Western Reserve University, Cleveland, OH; Seidman Cancer Center at University Hospitals Cleveland Medical Center, Cleveland, OH; University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH; Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA	Phase Ib/II neoadjuvant (N-) pembrolizumab (P) and chemotherapy for locally advanced urothelial cancer (laUC): Final results from the cisplatin (C)- eligible cohort of HCRN GU14-188.	Poster	Genitourinary Cancer—Kidney and Bladder	https://meetinglibrary.asco.org/record/187298/abstract
Primo Lara, Edward Mayerson, Erik Gertz, Catherine Tangen, Amir Goldkorn, Marta Van Loan, Maha H. A. Hussain, Shilpa Gupta, Jingsong Zhang, Przemyslaw Twardowski, David I. Quinn, Nicholas J. Vogelzang , Ian Murchie Thompson, Neeraj Agarwal ; University of California, Sacramento, CA; SWOG Statistical Center, Seattle, WA; USDA, WHNRC, Davis, CA; SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA; Division of Medical Oncology, Department of Medicine, Keck School of Medicine and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA; USDA, Davis, CA; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL; Cleveland Clinic Foundation, Cleveland, OH; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; City of Hope, Duarte, CA; USC Norris Comprehensive Cancer Center, Los Angeles, CA; Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Christus Santa Rosa Hospital-Medical Center, San Antonio, TX; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT	Bone metabolism biomarkers (BMB) and progression-free survival (PFS) in men with metastatic hormone-sensitive prostate cancer (HSPC): SWOG S1216, a phase III trial of androgen deprivation therapy (ADT) with or without orteronel.	Poster	Genitourinary Cancer—Prostate, Testicular, and Penile	https://meetinglibrary.asco.org/record/187818/abstract
Anthony R. Mato, Jeff P. Sharman , Juliana Biondo, Mei Wu, Yong Mun, Su Young Kim, Kathryn Humphrey, Michelle Boyer, Qian Zhu, John F. Seymour; Center for CLL, Memorial Sloan Kettering Cancer Center, New York, NY; Willamette Valley Cancer Institute and US Oncology Research Center, Eugene, OR; Genentech, Inc., South San Francisco, CA; AbbVie Inc., North Chicago, IL; Roche Products Limited, Welwyn Garden City, United Kingdom; Peter MacCallum Cancer Centre, Royal Melbourne Hospital, The University of Melbourne, Melbourne, Australia	Impact of premature venetoclax (Ven) discontinuation/interruption on outcomes in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Phase III MURANO study results.	Poster	Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia	https://meetinglibrary.asco.org/record/190051/abstract

Authors	Title	Presentation Type	Session	Link
Yen Thi Kim Hong Cao, Janson Trieu, Vanessa Rojas, Michael Elias, Michael J. Anderson, Nicholas J. Vogelzang ; University of Nevada Las Vegas, Las Vegas, NV; Comprehensive Cancer Centers of Nevada, Las Vegas, NV	Osteonecrosis of the jaw (ONJ) in radium 223 (Ra223)-treated metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with exposure to zoledronic acid and/or denosumab.	Poster	Genitourinary Cancer—Prostate, Testicular, and Penile	https://meetinglibrary.asco.org/record/188297/abstract
Michael Rahman Shafique, Terrence Lee Fisher, Elizabeth E. Evans, John E. Leonard, Desa Rae Electa Pastore, Crystal L. Mallow, Ernest Smith, Andreas Schröder, Kevin M. Chin, Joseph Thaddeus Beck, Megan Ann Baumgart, Ramaswamy Govindan, Nashat Y. Gabrail, Rachel E. Sanborn, Alexander I. Spira , Nagashree Seetharamu, Yanyan Lou, Aaron Scott Mansfield, Jonathan Wade Goldman, Maurice Zauderer; Department of Thoracic Oncology, Moffitt Cancer Center and Research Institute, Tampa, FL; Vaccinex, Inc., Rochester, NY; Merck KGaA, Darmstadt, Germany; EMD Serono, Inc., Billerica, MA; Highlands Oncology Group, Fayetteville, AR; University of Rochester, Rochester, NY; Washington University School of Medicine, St. Louis, MO; Gabrail Cancer Center, Canton, OH; Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR; Virginia Cancer Specialists, Fairfax, VA; Northwell Health Cancer Institute, Lake Success, NY; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Rochester, MN; Ronald Reagan UCLA Medical Center, Los Angeles, CA	Interim subgroup analysis for response by PD-L1 status of CLASSICAL-Lung, a phase Ib/II study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC.	Poster	Developmental Therapeutics—Immunotherapy	https://meetinglibrary.asco.org/record/185051/abstract
Charles G. Drake, Melissa Lynne Johnson, Alexander I. Spira , Gulam Abbas Manji, David Paul Carbone, Brian S. Henick, Matthew Ingham, Chih-Yi Liao, Sameek Roychowdhury, Chrisann Kyi, Paul Andrew Basciano, Eirini Bournazou, Jesse Abhyankar, Ashish Bezawada, Sonia Kounavouth, Desiree Schenk, Andrew R. Ferguson, Raphael F. Rousseau, Daniel V.T. Catenacci; Herbert Irving Comprehensive Cancer Center, New York, NY; Sarah Cannon Research Institute, Nashville, TN; Virginia Cancer Specialists, Fairfax, VA; Columbia University Herbert Irving Comprehensive Cancer Center, New York, NY; The Ohio State University Comprehensive Cancer Center, Columbus, OH; Yale School of Medicine, New Haven, CT; Columbia University Irving Medical Center, New York, NY; Barnes Jewish Hospital, St. Louis, MO; Ohio State University, Columbus, OH; Memorial Sloan Kettering Cancer Center, New York, NY; Bristol-Myers Squibb, Princeton, NJ; Gritstone Oncology, Emeryville, CA; University of Chicago Medical Center and Biological Sciences, Chicago, IL	Personalized viral-based prime/boost immunotherapy targeting patient-specific or shared neoantigens: Immunogenicity, safety, and efficacy results from two ongoing phase I studies.	Poster	Developmental Therapeutics—Immunotherapy	https://meetinglibrary.asco.org/record/188921/abstract
W. Kevin Kelly, Daniel Costin Danila, William Jeffery Edenfield , Rahul Raj Aggarwal, Daniel Peter Petrylak, A. Oliver Sartor, Christopher Joseph Sumey, Tanya B. Dorff, Evan Y. Yu, Nabil Adra, David Michael Waterhouse , Andrew J. Armstrong, Lisa Horvath, David William Pook, Leonard Joseph Appleman, Aubrey Lau, Mark Salvati, Hosein Kouros-Mehr; Thomas Jefferson University, Philadelphia, PA; Memorial Sloan Kettering Cancer Center, New York, NY; Prisma Health Greenville Memorial Hospital, Greenville, SC; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Yale Cancer Center, New Haven, CT; Tulane Cancer Center, New Orleans, LA; Sanford Cancer Center, Sioux Falls, SD; City of Hope, Duarte, CA; University of Washington, Seattle, WA; Indiana University School of Medicine, Indianapolis, IN; OHC (Oncology Hematology Care), Inc., Cincinnati, OH; Duke University School of Medicine, Durham, NC; Chris O'Brien Lifehouse, Camperdown, NSW, Australia; Monash University, Melbourne, VIC, Australia; UPMC Hillman Cancer Center, Pittsburgh, PA; Amgen Inc., Thousand Oaks, CA	Phase I study of AMG 509, a STEAP1 x CD3 T cell-recruiting XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC).	Poster	Genitourinary Cancer—Prostate, Testicular, and Penile	https://meetinglibrary.asco.org/record/191814/abstract
John D. Powderly, Sekwon Jang, Joanna Lohr, Alexander I. Spira , Gerry C. Bohac, Manish Sharma; Carolina BioOncology Institute, Huntersville, NC; Inova Schar Cancer Institute, Fairfax, VA; MacroGenics, Inc., Rockville, MD; Virginia Cancer Specialists, Fairfax, VA; University of Chicago, Chicago, IL	Preliminary dose escalation results from a phase I/II, first-in-human study of MGCO18 (anti-B7-H3 antibody-drug conjugate) in patients with advanced solid tumors.	Poster	Developmental Therapeutics—Immunotherapy	https://meetinglibrary.asco.org/record/188640/abstract

Authors	Title	Presentation Type	Session	Link
Robin Lewis Jones, Thomas J. Herzog, Shreyaskumar Patel, Margaret von Mehren, Scott Schuetze, Brian Andrew Van Tine, Robert L. Coleman , Spyridon Triantos, Peter Hu, Waleed Shalaby, Tracy McGowan, Bradley J. Monk , George D. Demetri; Royal Marsden Hospital/Institute of Cancer Research, London, United Kingdom; University of Cincinnati, University of Cincinnati Cancer Institute, Cincinnati, OH; The University of Texas MD Anderson Cancer Center, Houston, TX; Fox Chase Cancer Center, Philadelphia, PA; University of Michigan, Ann Arbor, MI; Siteman Cancer Center, Washington University in St. Louis, St. Louis, MO; Janssen Research and Development, Spring House, PA; Janssen Research & Development, LLC, Raritan, NJ; Janssen Scientific Affairs, LLC, Horsham, PA; Janssen Pharmaceuticals, Horsham, PA; Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Phoenix, AZ; Dana-Farber Cancer Institute, Boston, MA	Cardiac safety of trabectedin monotherapy and in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer.	Poster	Sarcoma	https://meetinglibrary.asco.org/record/186731/abstract
Stephen V. Liu, Ari M. Vanderwalde, Hirva Mamdani, Luis E. Raez, Yasmine Baca, Joanne Xiu, Wolfgang Michael Korn, Misako Nagasaka, Sachin Gopalkrishna Pai, Mark A. Socinski, Jorge J. Nieva, Chul Kim, Antoinette J. Wozniak, Chukwuemeka Ikpeazu, Gilberto Lopes, Alexander I. Spira , Julia Judd, Edward S. Kim, Hossein Borghaei; Georgetown University, Washington, DC; The University of Tennessee Health Science Center, West Cancer Center, Germantown, TN; Barbara Ann Karmanos Cancer Institute, Detroit, MI; Memorial Cancer Institute, Florida International University, Miami, FL; Caris Life Sciences, Phoenix, AZ; University of California San Francisco, San Francisco, CA; University of South Alabama, Mobile, AL; AdventHealth Cancer Institute, Orlando, FL; University of Southern California, Los Angeles, CA; Room 417 (pod B, second floor), Washington, DC; Hillman Cancer Center University of Pittsburgh, Pittsburgh, PA; University of Miami Sylvester Comprehensive Cancer Center, Plantation, FL; University of Miami Health System, Miami, FL; Virginia Cancer Specialists, Fairfax, VA; Temple University Health System, Philadelphia, PA; Levine Cancer Institute/Atrium Health, Charlotte, NC; Fox Chase Cancer Center, Philadelphia, PA	Characterization of KRAS mutations (mt) in non-small cell lung cancer (NSCLC).	Poster	Lung Cancer—Non-Small Cell Metastatic	https://meetinglibrary.asco.org/record/184890/abstract
Sushma Jonna, Rebecca Feldman, Sai-Hong Ignatius Ou, Misako Nagasaka, Jeffrey Swensen, Wolfgang Michael Korn, Hossein Borghaei, Ari M. Vanderwalde, Gilberto Lopes, Jorge J. Nieva, Alexander I. Spira , Edward S. Kim, Stephen V. Liu; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Caris Life Sciences, Phoenix, AZ; Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, CA; Barbara Ann Karmanos Cancer Institute, Detroit, MI; University of California San Francisco, San Francisco, CA; Fox Chase Cancer Center, Philadelphia, PA; The University of Tennessee Health Science Center, West Cancer Center, Germantown, TN; University of Miami Health System, Miami, FL; University of Southern California, Los Angeles, CA; Virginia Cancer Specialists, Fairfax, VA; Levine Cancer Institute/Atrium Health, Charlotte, NC; Georgetown University, Washington, DC	Characterization of NRG1 gene fusion events in solid tumors.	Poster	Developmental Therapeutics—Immunotherapy	https://meetinglibrary.asco.org/record/188615/abstract
Valentina Boni, Howard A. Burris III, Joyce F. Liu, Alexander I. Spira , Hendrik-Tobias Arkenau, Mary J. Fidler, Lee S. Rosen, Randy F. Sweis, Nataliya Volodymyrivna Uboha, Rachel E. Sanborn, Bert O'Neil, James J. Harding, Patricia LoRusso, Amy M. Weise, Javier Garcia-Corbacho, Iván Victoria, John W. Frye, Rachel Li, Mark Stroh, Funda Meric-Bernstam; START Madrid, CIOCC, Madrid, Spain; Sarah Cannon Research Institute (SCRI), Nashville, TN; Dana-Farber Cancer Institute, Boston, MA; Virginia Cancer Specialists, Fairfax, VA; Sarah Cannon Research Institute UK Limited, London, United Kingdom; Rush University Medical Center, Chicago, IL; UCLA Medical Centre-Santa Monica Hematology and Oncology, Santa Monica, CA; The University of Chicago, Department of Medicine, Chicago, IL; UW Carbone Cancer Center, Madison, WI; Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Memorial Sloan Kettering Cancer Center, New York, NY; Yale University School of Medicine, New Haven, CT; Karmanos Cancer Institute, Detroit, MI; Hospital Clínic de Barcelona, Barcelona, Spain; CytomX Therapeutics, Inc., South San Francisco, CA; University of Texas MD Anderson Cancer Center, Houston, TX	CX-2009, a CD166-directed probody drug conjugate (PDC): Results from the first-in-human study in patients (Pts) with advanced cancer including breast cancer (BC).	Poster	Breast Cancer—Local/Regional/Adjuvant	https://meetinglibrary.asco.org/record/190810/abstract
Debra A. Patt , Bo He, Jody S. Garey, Paul Rowan, Michael D Swartz, Stephen Linder, Barry Don Brooks , Marcus A. Neubauer ; McKesson Specialty Health and US Oncology Network, The Woodlands, TX; McKesson Specialty Health, The Woodlands, TX; US Oncology, Houston, TX; University of Texas School of Public Health, Houston, TX; The University of Texas School of Public Health, Houston, TX; US Oncology, The Woodlands, TX; The US Oncology Network/McKesson Specialty Health, Seattle, WA	Driving quality improvement: How clinical decision support can facilitate compliance with evidence-based pathways.	Poster	Care Delivery and Regulatory Policy	https://meetinglibrary.asco.org/record/187164/abstract

Authors	Title	Presentation Type	Session	Link
David Michael Waterhouse , Andrew Guinigundo, Aimee Brown, Dan Davies, Lauren Jones, Molly Mendenhall; OHC (Oncology Hematology Care)/US Oncology Network, Cincinnati, OH	First year outcomes of an initiative to increase BRCA testing among NCCN guideline-eligible breast cancer patients within a large community OCM practice.	Poster	Cancer Prevention, Risk Reduction, and Genetics	https://meetinglibrary.asco.org/record/188536/abstract
Meera Patel, Andrew Elliott, Stephen V. Liu, Chul Kim, Luis E. Raez, Rebecca Feldman, Sachin Gopalkrishna Pai, Antoinette J. Wozniak, Misako Nagasaka, Gilberto Lopes, Alexander I. Spira , Edward S. Kim, Wolfgang Michael Korn, Hirva Mamdani; Wayne State University/Karmanos Cancer Institute, Detroit, MI; CARIS Life Sciences, Irving, TX; Georgetown University, Washington, DC; Room 417 (pod B, second floor), Washington, DC; Memorial Cancer Institute, Florida International University, Miami, FL; Caris Life Sciences, Phoenix, AZ; Robert H. Lurie Cancer Center of Northwestern University, Chicago, IL; Hillman Cancer Center University of Pittsburgh, Pittsburgh, PA; Barbara Ann Karmanos Cancer Institute, Detroit, MI; University of Miami Health System, Miami, FL; Virginia Cancer Specialists, Fairfax, VA; Levine Cancer Institute/Atrium Health, Charlotte, NC; University of California San Francisco, San Francisco, CA	Genomic landscape and immune phenotype of malignant pleural mesothelioma.	Poster	Lung Cancer—Non-Small Cell Local-Regional/ Small Cell/Other Thoracic Cancers	https://meetinglibrary.asco.org/record/187001/abstract
Sami Diab, Matei P. Socoteanu, Carlos A. Encarnacion, Cynthia R. C. Osborne, Carolyn B. Hendricks, Kristi McIntyre, Vibha Taneja Thomas , Rajith Bhaskaran, Lorenza Mittempergher, Andrea Menicucci, William Audeh, Joyce O'Shaughnessy, FLEX Investigators' Group; Rocky Mountain Cancer Center-Aurora, Aurora, CO; Texas Oncology-Longview Cancer Center, US Oncology, Longview, TX; Texas Oncology-Waco, US Oncology, Waco, TX; Texas Oncology-Baylor Sammons Cancer Center, US Oncology, Dallas, TX; Maryland Oncology Hematology, Bethesda, MD; Texas Oncology-Presbyterian, US Oncology, Dallas, TX; Texas Oncology-Flower Mound, US Oncology, Flower Mound, TX; Research and Development, Agendia NV, Amsterdam, Netherlands; Medical Affairs, Agendia, Inc., Irvine, CA	High-risk breast cancer genes at 8q22-24 and their role in over 5,000 patients evaluated with the 70-gene risk of recurrence assay.	Poster	Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology	https://meetinglibrary.asco.org/record/187883/abstract
Jared Weiss, Jerome Goldschmidt , Andric Zoran, Konstantin H. Dragnev, Yili Pritchett, Shannon R. Morris, Rajesh K. Malik, Davey B. Daniel; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC; US Oncology Research, McKesson Specialty Health, Blacksburg, VA; University Hospital Medical Center Bezanijska Kosa, Belgrade, Serbia; Norris Cotton Cancer Center Dartmouth-Hitchcock, Lebanon, NH	Myelopreservation and reduced use of supportive care with trilaciclib in patients with small cell lung cancer.	Poster	Symptoms and Survivorship	https://meetinglibrary.asco.org/record/188196/abstract
Ignace Vergote, Nicole Concin, Mansoor Raza Mirza, Camilla Mondrup Andreassen, Domenica Lorusso, Christine N. Gennigens, Susana N. Banerjee, Roisin Eilish O'Cearbhaill, Susana Campos, Leonardo Viana Nicacio, Lamar Eaton, David M. O'Malley, Ibrahima Soumaoro, Bradley J. Monk ; Belgium and Luxembourg Gynaecological Oncology Group, University of Leuven, Leuven Cancer Institute, Leuven, Belgium; Nordic Society of Gynaecological Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; Genmab, Copenhagen, Denmark; Fondazione IRCCS, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Istituto Nazionale dei Tumori, Milan, Italy; Centre Hospitalier Universitaire de Liège, Liège, Belgium; The Royal Marsden NHS Foundation Trust, London, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Dana-Farber Cancer Institute, Boston, MA; Seattle Genetics, Inc., Bothell, WA; Genmab US, Inc, Princeton, NJ; The Ohio State University Comprehensive Cancer Center, Columbus, OH; St Joseph's Hospital and Medical Center, Phoenix, AZ	Phase Ib/II trial of tisotumab vedotin (TV) ± bevacizumab (BEV), pembrolizumab (PEM), or carboplatin (CBP) in recurrent or metastatic cervical cancer (innovaTV 205/ENGOT-cx8/GOG-3024).	Poster	Gynecologic Cancer	https://meetinglibrary.asco.org/record/191701/abstract

Authors	Title	Presentation Type	Session	Link
Rodney Paul Rocconi, Elizabeth A. Grosen, Sharad A. Ghamande, John K. Chan, Minal A. Barve, Jonathan Oh , Devansu Tewari, Peter C. Morris, Erin E. Stevens, Justin N. Bottsford-Miller, Min Tang, Phylicia Aaron, Gladice Wallraven, Ernest Bogнар, Luisa Manning, John J. Nemunaitis, Brian M. Slomovitz, Thomas J Herzog, Bradley J. Monk, Robert L. Coleman , Vigil Team; University of South Alabama, Mobile, AL; Cancer Care Northwest, Spokane, WA; Georgia Regents University, Augusta, GA; California Pacific Medical Center Research Institute, San Francisco, CA; Mary Crowley Cancer Research Center, Dallas, TX; Texas Oncology, Dallas, TX; Kaiser Permanente, Newport Coast, CA; Nebraska Methodist Hospital, Omaha, NE; Billings Clinic, Billings, MT; StatBeyond Consulting, LLC., Irvine, CA; Gradalis, Inc., Carrollton, TX; Gradalis, Inc., Dallas, TX; University of Miami, Miami, FL; Division of Gynecologic Oncology, The University of Cincinnati Cancer Institute, Cincinnati, OH; Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Phoenix, AZ; The University of Texas MD Anderson Cancer Center, Houston, TX	Randomized double-blind placebo-controlled trial of primary maintenance GMCSF/bi-shRNA(furin) DNA-transfected autologous tumor immunotherapy (VITAL study) in stage III/IV ovarian cancer: Efficacy assessment in BRCA1/2-wt patients.	Poster	Gynecologic Cancer	https://meetinglibrary.asco.org/record/185444/abstract
Robert M. Jotte , Marta Batus, Eric Bernicker, Mehmet Sitki Copur, Eli Kirshner, Han A. Koh, Mark Kozloff, Kert D. Sabbath, Janakiraman Subramanian, Wei Yu, Michael Nowicki, Ilze Bara, Gene Grant Finley; US Oncology Research and Rocky Mountain Cancer Centers, Denver, CO; Rush University Medical Center, Chicago, IL; Houston Methodist Hospital, Department of Medical Oncology, Houston, TX; Morrison Cancer Center Mary Lanning Healthcare, Hastings, NE; Valley Health System, Westwood, NJ; Kaiser Permanente, Bellflower, CA; UChicago Medicine Ingalls Memorial Hospital, Harvey, IL; The Harold Leever Regional Cancer Center, Yale School of Medicine, Waterbury, CT; Saint Luke's Health System, University of Kansas, Kansas City, MO; Genentech, Inc., South San Francisco, CA; Genentech, Inc, South San Francisco, CA; Department of Medical Oncology, Allegheny General Hospital, Pittsburgh, PA	IMpower150: Exploratory efficacy analysis in patients (pts) with bulky disease.	Publication	Lung Cancer–Non-Small Cell Metastatic	https://meetinglibrary.asco.org/record/185592/abstract
Saulius Kazmiems Girnius, Habte Aragaw Yimer, Sudhir Manda, Christopher A. Yasenachak , Veena Charu, Roger M. Lyons , Suman Kambhampati, Reumu E. Birhiray, Hares S. Jhangiani, Ralph V. Boccia, Presley Whidden, Kim Bogard, Dasha Cherepanov, Stephen Joseph Noga, Robert M. Rifkin ; Trihealth Cancer Institute, Cincinnati, OH; Texas Oncology/US Oncology Research, Tyler, TX; Arizona Oncology/US Oncology Research, Tucson, AZ; Willamette Valley Cancer Institute and Research Center/US Oncology Research, Eugene, OR; Pacific Cancer Medical Center, Anaheim, CA; Texas Oncology/US Oncology Research, San Antonio, TX; Kansas City Veterans Affairs Medical Center, Kansas City, MO; Hematology Oncology of Indiana/American Oncology Network, Indianapolis, IN; Compassionate Cancer Care Medical Group, Fountain Valley, CA; Center for Cancer and Blood Disorders, Bethesda, MD; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA; Rocky Mountain Cancer Centers, US Oncology Research, Denver, CO	Long-term proteasome inhibition in US community multiple myeloma (MM) patients (pts) following in-class transition (iCT) from parenteral bortezomib (V) to oral ixazomib (I): updated real-world (RW) data from US MM-6.	Publication	Publication Only: Health Services Research and Quality Improvement	https://meetinglibrary.asco.org/record/190425/abstract
Robert M. Jotte, Jerome H. Goldschmidt , Jeffrey Gary Schneider, Merrill Kingman Shum, David Berz, Lasika C. Seneviratne, Matei P. Socoteanu , Annie Hung, Rebecca R. Hozak, Bo H. Chao, John J. Nemunaitis; US Oncology Research and Rocky Mountain Cancer Centers, Denver, CO; Oncology and Hematology Assoc of SW Virginia, Blacksburg, VA; NYU Winthrop Hospital, Mineola, NY; The Onc Inst of Hope and Innovation, Whittier, CA; Beverly Hills Cancer Center, Beverly Hills, CA; Los Angeles Cancer Network, Los Angeles, CA; Texas Oncology-Longview Cancer Center, US Oncology, Longview, TX; Eli Lilly and Company, Indianapolis, IN; Eli Lilly and Company, New York, NY; Gradalis, Inc., Dallas, TX	Randomized phase II study of nivolumab (N) alone versus with pegilodocakin (PEG) in combination with N in patients (pts) with post-platinum immunotherapy-naive stage IV non-small cell lung cancer (NSCLC) and no or low PD-L1 expression (CYPRESS 2).	Publication	Lung Cancer–Non-Small Cell Metastatic	https://meetinglibrary.asco.org/record/185687/abstract
Alexander I. Spira, Paul R. Conkling , Melissa Lynne Johnson, Olivia Gardner, Houston N. Gilbert, Michael Scharville, Fangfang Yin, Kartik Krishnan, Melissa Constance Paoloni, Arvind Chaudhry; Virginia Cancer Specialists, Fairfax, VA; Virginia Oncology Associates, Norfolk, VA; Sarah Cannon Research Institute, Tennessee Oncology, PLLC, Nashville, TN; Arcus Biosciences, Hayward, CA; Med Onc Assoc P S, Spokane, WA	ARC-4 study: Efficacy and safety of AB928 plus carboplatin, pemetrexed and a PD-1 antibody in participants with metastatic non-small cell lung cancer (mNSCLC).	Publication	Publication Only: Lung Cancer–Non-Small Cell Metastatic	https://meetinglibrary.asco.org/record/185601/abstract

Authors	Title	Presentation Type	Session	Link
Robert M. Rifkin , Zoe Clancy, Ronda Copher, Kathleen M. Aguilar , Yiqiong Xie, Marley Boyd , Chuck Wentworth; Rocky Mountain Cancer Centers, US Oncology Research, Denver, CO; Bristol-Myers Squibb, Summit, NJ; McKesson Life Sciences, The Woodlands, TX	A real-world comparative analysis of pomalidomide (POM) and other antimyeloma treatments following lenalidomide (LEN) discontinuation among patients with multiple myeloma.	Publication	Publication Only: Health Services Research and Quality Improvement	https://meetinglibrary.asco.org/record/190731/abstract
Brigham Walker ; McKesson Specialty Health, The Woodlands, TX	Early physician spillover responses to the oncology care model.	Publication	Publication Only: Health Services Research and Quality Improvement	https://meetinglibrary.asco.org/record/190588/abstract
Sanjeev Balu, Joyce O'Shaughnessy , Mary Lisha Paul, Bismark Baidoo, Lavanya Sudharshan ; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; McKesson Life Sciences, The Woodlands, TX	EARLY real-world treatment and dosing patterns of ribociclib for metastatic breast cancer (mBC): A retrospective observational study.	Publication	Publication Only: Breast Cancer—Metastatic	https://meetinglibrary.asco.org/record/185227/abstract
Donna R. R Rivera, Laura Lasiter, Jennifer Christian, Lindsey Enewold, Janet L. Espirito , Eric Hansen, Henry J. Henk, Lawrence H. Kushi, Daniel Lane, Yanina Natanzon, Ruth Pe Benito, Erik Rasmussen, Nicholas J. Robert , Mark Stewart, Connor Sweetnam, Olga Tymejczyk, Emily Valice, Joseph Wagner, Alia Zander, Jeff Allen; National Cancer Institute, Rockville, MD; Friends of Cancer Research, Washington, DC; IQVIA, Research Triangle Park, NC; National Cancer Institute, Bethesda, MD; McKesson Life Sciences, The Woodlands, TX; COTA, Inc., New York, NY; OptumLabs, Shakopee, MN; Kaiser Permanente, Oakland, CA; COTA Healthcare, Boston, MA; Syapse, San Francisco, CA; Tempus, Chicago, IL; Flatiron Health, New York, NY; 10101 Woodloch Forest, The Woodlands, TX; Syapse Inc., San Francisco, CA; Kaiser Permanente Division of Research, Oakland, CA; IQVIA, Plymouth Meeting, PA	Overall survival (OS) in advanced non-small cell lung cancer (aNSCLC) patients treated with frontline chemotherapy or immunotherapy by comorbidity: A real-world data (RWD) collaboration.	Publication	Publication Only: Health Services Research and Quality Improvement	https://meetinglibrary.asco.org/record/190504/abstract
Thao Vo, Marley Boyd, Janet L. Espirito , Burak Gumuscu, Diana Romana Chirovsky, Nicholas J. Robert , Ramona F. Swaby, Wei Zhou, Charles Lance Cowey ; Merck, Kenilworth, NJ; McKesson Life Sciences, The Woodlands, TX; Merck & Co., Inc., Kenilworth, NJ; Merck and Co., Inc., Jersey City, NJ; Baylor-Sammons Cancer Ctr TOPA, Frisco, TX	Real-world (RW) systemic treatment patterns and clinical outcomes in locally advanced (LA) and recurrent or metastatic (R/M) cutaneous squamous cell carcinoma (cSCC) patients (pts).	Publication	Publication Only: Health Services Research and Quality Improvement	https://meetinglibrary.asco.org/record/190643/abstract
Charles Lance Cowey , Frank Xiaoqing Liu, Ruth Kim, Marley Boyd , Nicole Fulcher , Stan Krulewicz, Vijay Kasturi, Abhijeet Bhanegaonkar; The US Oncology Network, McKesson Life Sciences, Houston, TX; EMD Serono Research & Development Institute, Inc., Rockland, MA; Pfizer, Inc., New York, NY; McKesson Life Sciences, The Woodlands, TX; Pfizer, Inc., Collegeville, PA	Real-world clinical outcomes in avelumab-treated patients (pts) in the United States (U.S.) from SPEAR-Merkel Study informing treatment Pathway decisions in Merkel cell carcinoma (MCC).	Publication	Publication Only: Melanoma/Skin Cancers	https://meetinglibrary.asco.org/record/189168/abstract
Nicholas J. Robert , Joyce O'Shaughnessy , Srinivas Annavarapu , Jie Zhou , Jesse Sussell, Anna Cheng, Anita Fung; 10101 Woodloch Forest, The Woodlands, TX; Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; McKesson Life Sciences, The Woodlands, TX; Genentech, Inc, South San Francisco, CA	Risk of recurrence in patients with HER2+ breast cancer who achieved a pathological complete response (pCR) after neoadjuvant pertuzumab and trastuzumab (nPT), and received adjuvant trastuzumab (aT): Real-world evidence.	Publication	Publication Only: Breast Cancer—Local/Regional/Adjuvant	https://meetinglibrary.asco.org/record/190991/abstract
Roger M. Lyons , Jalaja Potluri, Cat Bui, Michelle E Choi, Esprit Ma, Anders Svensson, Kalatu Davies , Srinivas Annavarapu , Tatyana Kapustyan; Texas Oncology and US Oncology Research, San Antonio, TX; AbbVie, Inc., North Chicago, IL; Genentech, Inc., South San Francisco, CA; McKesson Life Sciences, The Woodlands, TX	Treatment outcomes and healthcare resource utilization (HRU) among patients with acute myeloid leukemia (AML) ineligible for intensive chemotherapy in US community oncology setting.	Publication	Publication Only: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant	https://meetinglibrary.asco.org/record/185335/abstract

Authors	Title	Presentation Type	Session	Link
Lawrence H. Kushi, Laura Lasiter, Andrew J. Belli, Marley Boyd , Suanna S. Bruinooge, Jennifer Christian, Elizabeth Garrett-Mayer, Eric Hansen, Rebecca Honnold, Ruth Pe Benito, Yanina Natanzon, Lori Sakoda, Donna R. R Rivera, Whitney Rhodes, Nicholas J. Robert , Elad Sharon, Connor Sweetnam, Joseph Wagner, Mark S. Walker, Jeff Allen; Kaiser Permanente, Oakland, CA; Friends of Cancer Research, Washington, DC; COTA, Inc., New York, NY; McKesson Life Sciences, The Woodlands, TX; American Society of Clinical Oncology, Alexandria, VA; IQVIA, Research Triangle Park, NC; Tempus Labs, Chicago; Tempus, Chicago, IL; Syapse, San Francisco, CA; Kaiser Permanente Northern California, Division of Research, Oakland, CA; National Cancer Institute, Rockville, MD; Concerto HealthAI, Memphis, TN; 10101 Woodloch Forest, The Woodlands, TX; National Cancer Institute, Bethesda, MD; Syapse Inc., San Francisco, CA; IQVIA, Plymouth Meeting, PA; ACORN Research LLC, Memphis, TN	Trends in immunotherapy use in patients with advanced non-small cell lung cancer (aNSCLC): Analysis of real-world data.	Publication	Publication Only: Health Services Research and Quality Improvement	https://meetinglibrary.asco.org/record/190528/abstract
Aimee Ginsburg, Lalan S. Wilfong, Neelima Denduluri, Josh Howell, Andrea Dickens, Kelly Leigh Casey, Angela Hsieh, John M. Burke, Charles Lance Cowey, J. Russell Hoverman, Lynne M. Knowles, Kartik Konduri, Tim Larson, Andrew Scott Paulson, Ian D. Schnadig, David Jacob Andorsky, Marcus A. Neubauer, Debra A. Patt ; The US Oncology Network/McKesson Specialty Health, The Woodlands, TX; Texas Oncology/The US Oncology Network, Dallas, TX; Virginia Cancer Specialists/The US Oncology Network, Arlington, VA; The US Oncology Network/McKesson Specialty Health, Houston, TX; Rocky Mountain Cancer Centers/The US Oncology Network, Aurora, CO; Texas Oncology/The US Oncology Network, Austin, TX; Minnesota Oncology/The US Oncology Network, Minneapolis, MN; Compass Oncology/The US Oncology Network, Tualatin, OR; Rocky Mountain Cancer Centers/The US Oncology Network, Boulder, CO; The US Oncology Network/McKesson Specialty Health, Seattle, WA; McKesson Specialty Health and US Oncology Network, The Woodlands, TX	Clinical decision support tools (CDST) provide education at the point-of-care to assist provider treatment choices.	Publication	Publication Only: Health Services Research and Quality Improvement	https://meetinglibrary.asco.org/record/190782/abstract
Russell Kent Pachynski, Rana R. McKay, Jason Hafron, Kate Fitch, Scott Flanders, Nicholas J. Vogelzang ; Washington University Medical School, St. Louis, MO; Dana-Farber Cancer Institute, Boston, MA; Michigan Institute of Urology, Troy, MI; Milliman, Inc., New York, NY; Dendreon Pharmaceuticals LLC, Seattle, WA; Comprehensive Cancer Centers of Nevada, Las Vegas, NV	Impact of flu vaccine on survival after immunotherapy for metastatic castration resistant prostate cancer (mCRPC): Analysis of Medicare claims data.	Publication	Publication Only: Genitourinary Cancer—Prostate, Testicular, and Penile	https://meetinglibrary.asco.org/record/188102/abstract
Dax Kurbegov, Patricia A. Hurley, David Michael Waterhouse , Grzegorz S. Nowakowski, Edward S. Kim; Sarah Cannon, the Cancer Institute of HCA Healthcare, Nashville, TN; American Society of Clinical Oncology, Alexandria, VA; OHC (Oncology Hematology Care), Inc., Cincinnati, OH; Mayo Clinic, Rochester, MN; Levine Cancer Institute/Atrium Health, Charlotte, NC	Transforming the site feasibility assessment process for oncology clinical trials.	Publication	Publication Only: Care Delivery and Regulatory Policy	https://meetinglibrary.asco.org/record/187199/abstract
Nicholas J. Vogelzang , Arash Rezazadeh Kalebasty, Richard Levin, Zulfiqar A. Malik, Ashley Ross, Britt Haley Bolemon , Nashat Y. Gabrail, Phoebe Zhang, Karl Zhou; Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Norton Cancer Institute, Louisville, KY; Chesapeake Urology Research Associates, Towson, MD; Suburban Medcl Plz II, Louisville, KY; Johns Hopkins Medicine, Baltimore, MD; Greenville Health System, Greenville, SC; Gabrail Cancer Center, Canton, OH; Kintor Pharmaceuticals, Inc., Chapel Hill, NC; Kintor Pharmaceuticals, Inc., Chape Hill, NC	Randomized multicenter open-label trial of GT0918 (proxalutamide) in patients with mCRPC that progressed on abiraterone or enzalutamide.	Publication	Publication Only: Genitourinary Cancer—Prostate, Testicular, and Penile	https://meetinglibrary.asco.org/record/188223/abstract
Maysa M. Abu-Khalaf, Christos Hatzis, K. Alex Hodge, Frances Valdes, William M. Sikov, Monica M. Mita, Neelima Denduluri , Kris Awerkamp, Rita Murphy, Daniel Zelterman, Bryant Dunetz, Emanuel Petricoin, Mariaelena Pierobon; Sidney Kimmel Cancer Center at Jefferson, Philadelphia, PA; Nuvera Biosciences Inc, Woburn, MA; George Mason University, Manassas, VA; University of Miami, Miami, FL; Women and Infants Hospital of Rhode Island, Providence, RI; Cedars-Sinai Comprehensive Cancer Center, Los Angeles, CA; The US Oncology Network, Arlington, VA; TD2 Inc., Scottsdale, AZ; Thomas Jefferson University, Philadelphia, PA; Yale School of Medicine, New Haven, CT; The Side-Out Foundation, Fairfax, VA; Perthera, Inc., Mclean, VA	CDK 4/6 drug target activation mapping of HR+ /HER2- metastatic breast cancer for treatment selection and response prediction.	Publication	Publication Only: Breast Cancer—Metastatic	https://meetinglibrary.asco.org/record/188558/abstract

Authors	Title	Presentation Type	Session	Link
Vijendra Singh, Rebecca Feldman, Ammar Sukari, Chul Kim, Hirva Mamdani, Alexander I. Spira , Gerold Bepler, Edward S. Kim, Luis E. Raez, Sachin Gopalkrishna Pai, Chukwuemeka Ikpeazu, Ari M. Vanderwalde, Joanne Xiu, Antoinette J. Wozniak, Hossein Borghaei, Stephen V. Liu, Misako Nagasaka; Department of Medicine, Wayne State University, Detroit, MI; Caris Life Sciences, Phoenix, AZ; Department of Oncology, Karmanos Cancer Institute/Wayne State University, Detroit, MI; Room 417 (pod B, second floor), Washington, DC; Barbara Ann Karmanos Cancer Institute, Detroit, MI; Virginia Cancer Specialists, Fairfax, VA; Karmanos Cancer Institute, Detroit, MI; Levine Cancer Institute, Atrium Health, Charlotte, NC; Memorial Cancer Institute, Florida International University, Miami, FL; Robert H. Lurie Cancer Center of Northwestern University, Chicago, IL; University of Miami Sylvester Comprehensive Cancer Center, Plantation, FL; The University of Tennessee Health Science Center, West Cancer Center, Germantown, TN; Hillman Cancer Center University of Pittsburgh, Pittsburgh, PA; Fox Chase Cancer Center, Philadelphia, PA; Georgetown University, Washington, DC	Characterization of ERBB2 alterations in non-small cell lung cancer.	Publication	Lung Cancer—Non-Small Cell Metastatic	https://meetinglibrary.asco.org/record/185681/abstract
Sharon Wilks, Kristi McIntyre , Linda K. Han, Michalina Marie Cairo , Julie Barone, Josien Haan, Lorenza Mitterpergher, Erin Yoder, Andrea Menicucci, Shiyu Wang, William Audeh, FLEX Investigators' Group; Texas Oncology-San Antonio Northeast, US Oncology, San Antonio, TX; Texas Oncology-Presbyterian, US Oncology, Dallas, TX; Parkview Cancer Institute, Fort Wayne, IN; Texas Oncology-Houston Memorial City, US Oncology, Houston, TX; SCL Health Medical Group, Denver, CO; Research and Development, Agendia NV, Amsterdam, Netherlands; Medical Affairs, Agendia, Inc., Irvine, CA;	Distinct molecular profiles of interval and screen-detected tumors in a real-world breast cancer registry.	Publication	Publication Only: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology	https://meetinglibrary.asco.org/record/188950/abstract
Bing Xia, Rebecca Feldman, Wendy Cozen, Irene Kang, Luis E. Raez, Hossein Borghaei, Chul Kim, Misako Nagasaka, Hirva Mamdani, Ari M. Vanderwalde, Sachin Gopalkrishna Pai, Gilberto Lopes, Mark A. Socinski, Antoinette J. Wozniak, Edward S. Kim, Alexander I. Spira , Stephen V. Liu, Jorge J. Nieva; University of Southern California, Los Angeles, CA; Caris Life Sciences, Phoenix, AZ; University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA; Memorial Cancer Institute, Florida International University, Miami, FL; Fox Chase Cancer Center, Philadelphia, PA; Room 417 (pod B, second floor), Washington, DC; Barbara Ann Karmanos Cancer Institute, Detroit, MI; The University of Tennessee Health Science Center, West Cancer Center, Germantown, TN; Robert H. Lurie Cancer Center of Northwestern University, Chicago, IL; University of Miami Health System, Miami, FL; AdventHealth Cancer Institute, Orlando, FL; Hillman Cancer Center University of Pittsburgh, Pittsburgh, PA; Levine Cancer Institute/Atrium Health, Charlotte, NC; Virginia Cancer Specialists, Fairfax, VA; Georgetown University, Washington, DC	Gender disparities in hormone positive lung cancer.	Publication	Lung Cancer—Non-Small Cell Metastatic	https://meetinglibrary.asco.org/record/185634/abstract

Learn More

usoncology.com/research
researchopportunities@mckesson.com
281.863.1000

©2020 McKesson Corporation. All rights reserved.
SPO-683667-05-20

MCKESSON

